Under Fire, Bristol Plans To Pick Up The IO Pieces
Facing analysts jittery about the prospects for Opdivo/Yervoy in first-line lung cancer, Bristol boasts breadth of Phase III lung program, including IO/chemo studies, and variety of tumor types targeted.
You may also be interested in...
Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.
Yervoy/Opdivo combo proves significant survival benefit over Yervoy alone in Phase III frontline melanoma study, but is on par with Opdivo alone in patients with higher PD-L1 expression.
New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum.